Feature image: RMIT researcher Dr Amgad Rezk
Acoustics experts at RMIT University have created a new class of sound wave – the first in more than half a century – in a breakthrough they hope could lead to a revolution in stem cell therapy.
The RMIT team combined two different types of acoustic sound waves called bulk waves and surface waves to create a new hybrid: “surface reflected bulk waves”.
The first new class of sound wave discovered in decades, the powerful waves are gentle enough to use in biomedical devices to manipulate highly fragile stem cells without causing damage or affecting their integrity, opening new possibilities in stem cell treatment.
Dr Amgad Rezk, from RMIT’s Micro/Nano Research Laboratory, said the team was already using the discovery to dramatically improve the efficiency of an innovative new “nebuliser” that could deliver vaccines and other drugs directly to the lung.
“We have used the new sound waves to slash the time required for inhaling vaccines through the nebuliser device, from 30 minutes to as little as 30 seconds,” Rezk says.
“But our work also opens up the possibility of using stem cells more efficiently for treating lung disease, enabling us to nebulise stem cells straight into a specific site within the lung to repair damaged tissue.
“This is a real game changer for stem cell treatment in the lungs.”
The researchers are using the “surface reflected bulk waves” in a breakthrough device, dubbed HYDRA, which converts electricity passing through a piezoelectric chip into mechanical vibration, or sound waves, which in turn break liquid into a spray.
“It’s basically ‘yelling’ at the liquid so it vibrates, breaking it down into vapour,” Rezk says.
Bulk sound waves operate similar to a carpet being held at one end and shaken, resulting in the whole substrate vibrating as one entity. Surface sound waves on the other hand operate more like ocean waves rolling above a swimmer’s head.
“The combination of surface and bulk wave means they work in harmony and produce a much more powerful wave,” says Rezk, who co-authored the study with PhD researcher James Tan.
“As a result, instead of administering or nebulising medicine at around 0.2 ml per minute, we did up to 5 ml per minute. That’s a huge difference.”
The breakthrough HYDRA device is improving the effectiveness of a revolutionary new type of nebuliser developed at RMIT called Respite. Cheap, lightweight and portable, the advanced Respitenebuliser can deliver everything from precise drug doses to patients with asthma and cystic fibrosis, to insulin for diabetes patients, and needle-free vaccinations to infants.
The HYDRA research has been published in the scientific journal Advanced Materials.
This article was first shared by RMIT University on 8 January 2016. Read the original article here.